Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
Engene Inc. Announces the Appointment of Dr. Dennis H. Langer to the Companys Board of Directors
December 9, 2015
Montreal, Canada -enGene, Inc., a gene therapy company focused on development of therapeutics using its proprietary Gene Pill and enema gene delivery platform, today announced the appointment of Dr. Dennis H. Langer to its Board of Directors.
Dr. Langer brings to enGene more than 25 years of executive and entrepreneurial experience in the pharmaceutical and biotechnology industry. He held several high--- level positions at GlaxoSmithKline from 1994 to 2004, including most recently as a Senior Vice President of Research and Development. Prior to that, Dr. Langer was President and CEO of Neose Technologies, Inc., and before that he held R&D and marketing positions at Eli Lilly, Abbott and Searle. Currently, Dr. Langer serves as a Director of Myriad Genetics, Inc., Dicerna Pharmaceuticals, Inc., Delcath Systems, Inc., and several private companies. Previously, Dr. Langer served as a Director of several very successful biotechnology companies, including, Ception Therapeutics, Inc. (acquired by Cephalon, Inc.), Sirna Therapeutics, Inc. (acquired by Merck and Co., Inc.), and Transkaryotic Therapies, Inc. (acquired by Shire plc). Dr. Langer received a J.D. from Harvard Law School, an MD from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University.
Dr. Langers impressive track record as a founder, CEO and director of several successful biotechnology companies and as Senior Vice President of R&D at GSK make him an ideal addition to enGenes Board, said Dr. Anthony T. Cheung, President and Chief Executive Officer of enGene. His wealth of experience in drug development and in building successful biotech companies will provide our company with valuable strategic perspective, as we expand our pipeline and advance our lead compound into clinical testing.
"I am delighted to be joining the Board of Directors of enGene, Inc. at this exciting time, following the recently announced partnership with Jansen, a division of Johnson & Johnson, which will enable the company to exploit its unique delivery technology for inducing protein expression in mucosal tissues, and advancing enGenes own products into clinical trials involving patients with significant unmet needs, " said Dennis H. Langer, M.D., J.D.
More about enGene
enGene Inc. is a privately held biotechnology company developing a versatile, proprietary non---viral vector platform for gene delivery to mucosal cells lining the gut. The vector system can be administered to the intestine via the oral or enema route. enGene is developing its unique gene delivery formulation into an orally available Gene Pill, which has the potential to be a platform for oral delivery of a wide range protein drugs. Its primary focus is targeting its technology to enable localize delivery of immune---modulating proteins to the gut for treating various immune disorders.